294 related articles for article (PubMed ID: 34427754)
1. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
Villanueva V; D'Souza W; Goji H; Kim DW; Liguori C; McMurray R; Najm I; Santamarina E; Steinhoff BJ; Vlasov P; Wu T; Trinka E;
J Neurol; 2022 Apr; 269(4):1957-1977. PubMed ID: 34427754
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.
Wheless J; Wechsler RT; Penovich P; Segal E; Chez M; Coppola A; Datta A; D'Souza W; Najm I; Cappucci S; Sainz-Fuertes R; Villanueva V
Epilepsy Behav; 2023 Oct; 147():109369. PubMed ID: 37619459
[TBL] [Abstract][Full Text] [Related]
3. Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study.
D'Souza W; Alsaadi T; Montoya J; Carreño M; Di Bonaventura C; Mohanraj R; Yamamoto T; McMurray R; Shastri O; Villanueva V;
Seizure; 2022 Aug; 100():56-66. PubMed ID: 35777333
[TBL] [Abstract][Full Text] [Related]
4. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice.
Trinka E; Alsaadi T; Goji H; Maehara T; Takahashi S; Jacobs J; Renna R; Gil-López FJ; McMurray R; Sáinz-Fuertes R; Villanueva V
Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853
[TBL] [Abstract][Full Text] [Related]
5. Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study.
Liguori C; Santamarina E; Strzelczyk A; Rodríguez-Uranga JJ; Shankar R; Rodríguez-Osorio X; Auvin S; Bonanni P; Trinka E; McMurray R; Sáinz-Fuertes R; Villanueva V
Front Neurol; 2023; 14():1120150. PubMed ID: 37064177
[TBL] [Abstract][Full Text] [Related]
6. Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study.
Delanty N; Mohanraj R; Shankar R; Wehner T; Stephen LJ; D'Souza W; Cappucci S; McMurray R; Sainz-Fuertes R; Villanueva V
Epilepsy Res; 2024 May; 202():107339. PubMed ID: 38492461
[TBL] [Abstract][Full Text] [Related]
7. Perampanel for Treatment of People with a Range of Epilepsy Aetiologies in Clinical Practice: Evidence from the PERMIT Extension Study.
Strzelczyk A; Maschio M; Pensel MC; Coppola A; Takahashi S; Izumoto S; Trinka E; Cappucci S; Sainz-Fuertes R; Villanueva V
Neurol Ther; 2024 Jun; 13(3):825-855. PubMed ID: 38678505
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry.
Toledano Delgado R; García-Morales I; Parejo-Carbonell B; Jiménez-Huete A; Herrera-Ramirez D; González-Hernández A; Ayuga Loro F; Santamarina E; Toledo M; Ojeda J; Poza JJ; Molins A; Giner P; Estévez María JC; Castro-Vilanova MD; Zurita J; Saiz-Diaz RA; Gómez-Ibañez A; Rodriguez-Uranga J; Gil-Nagel A; Campos D; Sánchez-Larsen Á; Aguilar-Amat Prior MJ; Mauri Llerda JA; Huertas González N; García-Barragán N
Epilepsia; 2020 Jun; 61(6):1109-1119. PubMed ID: 32511754
[TBL] [Abstract][Full Text] [Related]
10. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures:A real-world experience in eastern China.
Xu S; Xu ZY; Zheng Y; Miao P; Feng J; Guo Y
Seizure; 2023 Aug; 110():231-237. PubMed ID: 37437408
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
[TBL] [Abstract][Full Text] [Related]
13. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
[TBL] [Abstract][Full Text] [Related]
15. The real-world effectiveness and safety of perampanel in Europe: A scoping review.
Estévez-María JC; Garamendi-Ruiz I
Epilepsy Behav; 2022 Sep; 134():108777. PubMed ID: 35816832
[TBL] [Abstract][Full Text] [Related]
16. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
[TBL] [Abstract][Full Text] [Related]
18. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
